Literature DB >> 26200036

Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study.

James Brian Byrd1, Richard J Auchus, Perrin C White.   

Abstract

BACKGROUND: A single-nucleotide polymorphism in the aldosterone synthase gene (CYP11B2) promoter [-344C/T, rs1799998] has been reported to associate with cardiovascular phenotypes.
METHODS: The Dallas Heart Study is a large, multiethnic cohort with a high prevalence of hypertension. We genotyped 3452 Dallas Heart Study participants for -344C/T. Generalized linear models were used to assess whether variation at -344C/T associated with plasma aldosterone concentration (PAC), systolic and diastolic blood pressure (SBP and DBP), plasma glucose (in persons with no diabetes), HOMA IR (Homeostasis Model Assessment as an Index of Insulin Resistance), and left ventricular (LV) mass indexed to height. Systolic blood pressure and DBP were significantly higher in blacks compared with whites (P < 0.001 for SBP and for DBP) and Hispanics (P < 0.001 for SBP and for DBP). Log-transformed body mass index was also significantly higher in blacks compared with whites (P < 0.001), but not Hispanics (P = 0.10). Log-transformed PAC was higher in whites compared with blacks (P < 0.001), but did not differ significantly in whites compared with Hispanics (P = 0.73). In univariate and multivariable analysis, -344C/T was not significantly associated with PAC within any ethnicity. In univariate and multivariable analysis, -344C/T was not associated with SBP or DBP within any ethnicity. After adjustment for multiple testing, univariate and multivariable analyses revealed no association between -344C/T and plasma glucose in patients with no diabetes, HOMA IR, or LV mass indexed to height.
CONCLUSIONS: We were unable to reproduce previously reported associations between -344C/T and PAC, blood pressure, plasma glucose, or LV mass. Methodological differences might explain the differences between our findings and those previously reported.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200036      PMCID: PMC5568080          DOI: 10.1097/JIM.0000000000000220

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  26 in total

1.  A note on exact tests of Hardy-Weinberg equilibrium.

Authors:  Janis E Wigginton; David J Cutler; Goncalo R Abecasis
Journal:  Am J Hum Genet       Date:  2005-03-23       Impact factor: 11.025

2.  Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion.

Authors:  Wiktoria Wojciechowska; Jan A Staessen; Katarzyna Stolarz; Tim Nawrot; Jan Filipovský; Milena Tichá; Giuseppe Bianchi; Eva Brand; Marcin Cwynar; Tomasz Grodzicki; Tatiana Kuznetsova; Harry A Struijker-Boudier; Vlasta Svobodová; Lutgarde Thijs; Luc M Van Bortel; Kalina Kawecka-Jaszcz
Journal:  J Hypertens       Date:  2004-12       Impact factor: 4.844

3.  Genetic polymorphism of CYP11B2 gene and stroke in the Han Chinese population and a meta-analysis.

Authors:  Yuanchao Tu; Guanglin Cui; Yujun Xu; Xunna Bao; Xiaojing Wang; Dao Wen Wang
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

4.  Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism.

Authors:  Guo-xi Zhang; Bao-jun Wang; Jin-zhi Ouyang; Xi-yuan Deng; Xin Ma; Hong-zhao Li; Zhun Wu; Shuang-lin Liu; Hua Xu; Xu Zhang
Journal:  Hypertens Res       Date:  2010-03-26       Impact factor: 3.872

5.  Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.

Authors:  Baojun Wang; Guoxi Zhang; Jinzhi Ouyang; Xiyuan Deng; Taoping Shi; Xin Ma; Hongzhao Li; Zhenghua Ju; Chao Wang; Zhun Wu; Shuanglin Liu; Xu Zhang
Journal:  Urology       Date:  2010-08-13       Impact factor: 2.649

6.  Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2.

Authors:  Mako Isaji; Tomoatsu Mune; Nobuki Takada; Yoritsuna Yamamoto; Tetsuya Suwa; Hiroyuki Morita; Jun Takeda; Perrin C White
Journal:  J Hypertens       Date:  2005-06       Impact factor: 4.844

7.  Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

Authors:  Lisa Kurland; Håkan Melhus; Julia Karlsson; Thomas Kahan; Karin Malmqvist; Peter Ohman; Fredrik Nyström; Anders Hägg; Lars Lind
Journal:  Am J Hypertens       Date:  2002-05       Impact factor: 2.689

8.  Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males.

Authors:  A Hautanena; L Lankinen; M Kupari; O A Jänne; H Adlercreutz; H Nikkilä; P C White
Journal:  J Intern Med       Date:  1998-07       Impact factor: 8.989

9.  Multiple Polymorphisms in the renin- angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort.

Authors:  Sean O Henderson; Christopher A Haiman; Wendy Mack
Journal:  Am J Med Sci       Date:  2004-11       Impact factor: 2.378

10.  Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension.

Authors:  Samantha Alvarez-Madrazo; Scott M Mackenzie; Eleanor Davies; Robert Fraser; Wai-Kwong Lee; Morris Brown; Mark J Caulfield; Anna F Dominiczak; Martin Farrall; Mark Lathrop; Thomas Hedner; Olle Melander; Patricia B Munroe; Nilesh Samani; Paul M Stewart; Björn Wahlstrand; John Webster; Colin N A Palmer; Sandosh Padmanabhan; John M Connell
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

View more
  1 in total

1.  Gene Polymorphisms of the Renin-Angiotensin-Aldosterone System as Risk Factors for the Development of In-Stent Restenosis in Patients with Stable Coronary Artery Disease.

Authors:  Madina Azova; Kalima Timizheva; Amira Ait Aissa; Mikhail Blagonravov; Olga Gigani; Anna Aghajanyan; Leyla Tskhovrebova
Journal:  Biomolecules       Date:  2021-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.